サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1416322

放射性リガンド治療市場レポート：2030年までの動向、予測、競合分析

Radioligand Therapy Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日: | 発行: Lucintel | ページ情報: 英文 150 - page report | 納期: 3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円

ご注意:　DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

放射性リガンド治療市場レポート：2030年までの動向、予測、競合分析
出版日: 2024年01月29日
発行: Lucintel
ページ情報: 英文 150 - page report
納期: 3営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

放射性リガンド治療の動向と予測

世界の放射性リガンド治療市場は、2024年から2030年までCAGR 5.0%で、2030年までに推定138億米ドルに達すると予想されています。この市場の主な促進要因は、がん罹患率の上昇と効果的な治療に対する高い需要です。世界の放射性リガンド治療市場の将来は、病院や診療所、診断センター市場での機会があり、有望に見えます。

放射性リガンド治療市場に関する洞察

Lucintelは、がん診断における高い需要により、フッ素-18が予測期間を通じて最大のセグメントであり続けると予測しています。

この市場では、座りっぱなしの生活様式の普及と世界中でがんの症例が増加しているため、病院が引き続き最大のセグメントとなるでしょう。

がんの専門病院や研究センターが存在し、地域全体でがんの発生率が増加しているため、北米は予測期間中も最大の地域であり続けると思われます。

よくある質問

Q1.市場規模は：

A1.世界の放射性リガンド治療市場は、2030年までに推定138億米ドルに達すると予想されています。

Q2.市場の成長予測は：

A2.世界の放射性リガンド治療市場は、2024年から2030年にかけて5.0%のCAGRで成長すると予想されています。

Q3.市場の成長に影響を与える主な促進要因は：

A3.この市場の主な促進要因は、がん罹患率の上昇と効果的な治療に対する高い需要です。

Q4.市場の主要セグメントは：

A4.放射性リガンド治療市場の将来は、病院や診療所、診断センター市場での機会があり、有望に見えます。

Q5.市場の主要企業は：

A5.主要な放射性リガンド治療会社は次のとおりです。

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma

Q6.今後、最大となる市場セグメントは：

A6.Lucintelは、がん診断における高い需要により、フッ素-18が予測期間を通じて最大のセグメントであり続けると予測しています。

Q7.市場において、今後5年間に最大になると予想される地域は：

A7.がんの専門病院や研究センターが存在し、地域全体でがんの発生率が増加しているため、北米は予測期間中も最大の地域であり続けると思われます。

Q8.レポートのカスタマイズは可能か：

A8.はい、Lucintelは追加費用なしで10%のカスタマイズを提供します。

目次

第1章 エグゼクティブサマリー

第2章 世界の放射性リガンド治療市場：市場力学

  • イントロダクション、背景、分類
  • サプライチェーン
  • 業界の促進要因と課題

第3章 2018年から2030年までの市場動向と予測分析

  • マクロ経済動向（2018～2023年）と予測（2024～2030年）
  • 世界の放射性リガンド治療市場の動向（2018-2023）と予測（2024-2030）
  • 同位体別の世界の放射性リガンド治療市場
    • フッ素-18
    • ガリウム-68
    • ルテチウム-177
    • その他
  • 標的受容体別の世界の放射性リガンド治療市場
    • 前立腺特異的膜抗原
    • ソマトスタチン受容体
    • 上皮成長因子受容体
    • その他
  • 適応症別の世界の放射性リガンド治療市場
    • 前立腺がん
    • 神経内分泌腫瘍
    • 乳がん
    • その他
  • 最終用途別の世界の放射性リガンド治療市場
    • 病院と診療所
    • 診断センター
    • その他

第4章 2018年から2030年までの地域別の市場動向と予測分析

  • 地域別の世界の放射性リガンド治療市場
  • 北米の放射性リガンド治療市場
  • 欧州の放射性リガンド治療市場
  • アジア太平洋の放射性リガンド治療市場
  • その他地域の放射性リガンド治療市場

第5章 競合の分析

  • 製品ポートフォリオ分析
  • 運用上の統合
  • ポーターのファイブフォース分析

第6章 成長機会と戦略的分析

  • 成長機会分析
    • 同位体別の世界の放射性リガンド治療市場の成長機会
    • 標的受容体別の世界の放射性リガンド治療市場の成長機会
    • 適応別の世界の放射性リガンド治療市場の成長機会
    • 最終用途別の世界の放射性リガンド治療市場の成長機会
    • 地域別の世界の放射性リガンド治療市場の成長機会
  • 世界の放射性リガンド治療市場における新たな動向
  • 戦略的分析
    • 新製品の開発
    • 世界の放射性リガンド治療市場の能力拡大
    • 世界の放射性リガンド治療市場における合併、買収、合弁事業
    • 認証とライセンシング

第7章 有力企業の企業プロファイル

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma
目次

Radioligand Therapy Trends and Forecast

The future of the global radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets. The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030 with a CAGR of 5.0% from 2024 to 2030. The major drivers for this market are rising cancer rates and high demand for effective treatment.

A more than 150-page report is developed to help in your business decisions.

Radioligand Therapy by Segment

The study includes a forecast for the global radioligand therapy by isotope, targeted receptor, indication, end use, and region.

Radioligand Therapy Market by Isotope [Shipment Analysis by Value from 2018 to 2030]:

  • Fluorine - 18
  • Gallium - 68
  • Lutetium - 177
  • Others

Radioligand Therapy Market by Targeted Receptor [Shipment Analysis by Value from 2018 to 2030]:

  • Prostate-Specific Membrane Antigen
  • Somatostatin Receptor
  • Epidermal Growth Factor Receptor
  • Others

Radioligand Therapy Market by Indication [Shipment Analysis by Value from 2018 to 2030]:

  • Prostate Cancer
  • Neuroendocrine Tumors
  • Breast Cancer
  • Others

Radioligand Therapy Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospitals & Clinics
  • Diagnostic Centers
  • Others

Radioligand Therapy Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Radioligand Therapy Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies radioligand therapy companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the radioligand therapy companies profiled in this report include-

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma

Radioligand Therapy Market Insights

Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.

Within this market, hospitals will remain the largest segment due to increasing prevalence of a sedentary way of living and growing cases of cancer across the globe.

North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.

Features of the Global Radioligand Therapy Market

Market Size Estimates: Radioligand therapy market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Radioligand therapy market size by various segments, such as by isotope, targeted receptor, indication, end use, and region in terms of value ($B).

Regional Analysis: Radioligand therapy market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different isotope, targeted receptor, indications, end uses, and regions for the radioligand therapy market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the radioligand therapy market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q1. What is the radioligand therapy market size?

Answer: The global radioligand therapy market is expected to reach an estimated $13.8 billion by 2030.

Q2. What is the growth forecast for radioligand therapy market?

Answer: The global radioligand therapy market is expected to grow with a CAGR of 5.0% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the radioligand therapy market?

Answer: The major drivers for this market are rising cancer rates and high demand for effective treatment.

Q4. What are the major segments for radioligand therapy market?

Answer: The future of the radioligand therapy market looks promising with opportunities in the hospitals & clinic and diagnostic center markets.

Q5. Who are the key radioligand therapy market companies?

Answer: Some of the key radioligand therapy companies are as follows:

  • Novartis
  • POINT Biopharma Global
  • Molecular Partners
  • Telix Pharmaceuticals
  • Fusion Pharma
  • Lantheus Holdings
  • Curium
  • Precrix
  • Orano
  • Artios Pharma

Q6. Which radioligand therapy market segment will be the largest in future?

Answer: Lucintel forecasts that flourine-18 will remain the largest segment over the forecast period due to high demand in cancer diagnosis.

Q7. In radioligand therapy market, which region is expected to be the largest in next 5 years?

Answer: North America will remain the largest region over the forecast period due to presence of specialized cancer hospitals and research centers and rising incidences of cancer across the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the radioligand therapy market by isotope (fluorine - 18, gallium - 68, lutetium - 177, and others), targeted receptor (prostate-specific membrane antigen, somatostatin receptor, epidermal growth factor receptor, and others), indication (prostate cancer, neuroendocrine tumors, breast cancer, and others), end use (hospitals & clinics, diagnostic centers, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Radioligand Therapy Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Radioligand Therapy Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Radioligand Therapy Market by Isotope
    • 3.3.1: Fluorine - 18
    • 3.3.2: Gallium - 68
    • 3.3.3: Lutetium - 177
    • 3.3.4: Others
  • 3.4: Global Radioligand Therapy Market by Targeted Receptor
    • 3.4.1: Prostate-specific Membrane Antigen
    • 3.4.2: Somatostatin Receptor
    • 3.4.3: Epidermal Growth Factor Receptor
    • 3.4.4: Others
  • 3.5: Global Radioligand Therapy Market by Indication
    • 3.5.1: Prostate Cancer
    • 3.5.2: Neuroendocrine Tumors
    • 3.5.3: Breast Cancer
    • 3.5.4: Others
  • 3.6: Global Radioligand Therapy Market by End Use
    • 3.6.1: Hospitals & Clinics
    • 3.6.2: Diagnostic Centers
    • 3.6.3: Others

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Radioligand Therapy Market by Region
  • 4.2: North American Radioligand Therapy Market
    • 4.2.2: North American Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
  • 4.3: European Radioligand Therapy Market
    • 4.3.1: European Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
    • 4.3.2: European Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
  • 4.4: APAC Radioligand Therapy Market
    • 4.4.1: APAC Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
    • 4.4.2: APAC Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others
  • 4.5: ROW Radioligand Therapy Market
    • 4.5.1: ROW Radioligand Therapy Market by Isotope: Fluorine - 18, Gallium - 68, Lutetium - 177, and Others
    • 4.5.2: ROW Radioligand Therapy Market by End Use: Hospitals & Clinics, Diagnostic Centers, and Others

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Radioligand Therapy Market by Isotope
    • 6.1.2: Growth Opportunities for the Global Radioligand Therapy Market by Targeted Receptor
    • 6.1.3: Growth Opportunities for the Global Radioligand Therapy Market by Indication
    • 6.1.4: Growth Opportunities for the Global Radioligand Therapy Market by End Use
    • 6.1.5: Growth Opportunities for the Global Radioligand Therapy Market by Region
  • 6.2: Emerging Trends in the Global Radioligand Therapy Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Radioligand Therapy Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Radioligand Therapy Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Novartis
  • 7.2: POINT Biopharma Global
  • 7.3: Molecular Partners
  • 7.4: Telix Pharmaceuticals
  • 7.5: Fusion Pharma
  • 7.6: Lantheus Holdings
  • 7.7: Curium
  • 7.8: Precrix
  • 7.9: Orano
  • 7.10: Artios Pharma